Mayo Clinic, Rochester, Minnesota, USA.
Curr Opin Rheumatol. 2010 May;22(3):342-7. doi: 10.1097/BOR.0b013e3283379b91.
The present review highlights the recent findings on cardiovascular disease in rheumatoid arthritis (RA), and outlines the current concepts and prospects of cardiovascular disease detection and management in RA.
Over the past year the knowledge of cardiovascular disease in RA has been augmented by a number of studies further explicating the interplay between RA and cardiovascular risk factors and highlighting the impact of inflammatory measures, immune mediators and other markers as early determinants of cardiovascular disease in RA. Other studies reported potential beneficial effects on cardiovascular outcomes for some antirheumatic medications.
Knowledge of the increased burden of cardiovascular disease in RA is substantial and is continuously growing. Early detection, control and management of cardiovascular disease in RA appear to be a rapidly advancing field of research. However, much more work is needed to develop effective interventions to reduce cardiovascular morbidity and mortality in RA patients. More studies are needed to identify specific biomarkers for cardiovascular disease in RA and to develop cardiovascular risk scoring tools and evidence-based algorithms to promote more effective cardiovascular prevention and management of cardiovascular disease in RA.
本综述强调了类风湿关节炎（RA）中心血管疾病的最新发现，并概述了 RA 中心血管疾病检测和管理的当前概念和前景。
在过去的一年中，多项研究进一步阐明了 RA 与心血管危险因素之间的相互作用，并强调了炎症指标、免疫介质和其他标志物作为 RA 中心血管疾病早期决定因素的作用，这些研究增加了对 RA 中心血管疾病的认识。其他研究报告了一些抗风湿药物对心血管结局的潜在有益影响。
RA 中心血管疾病负担增加的知识是实质性的，并且在不断增加。RA 中心血管疾病的早期检测、控制和管理似乎是一个快速发展的研究领域。然而，需要做更多的工作来开发有效的干预措施，以降低 RA 患者的心血管发病率和死亡率。需要更多的研究来确定 RA 中心血管疾病的特定生物标志物，并开发心血管风险评分工具和基于证据的算法，以促进更有效的 RA 中心血管疾病预防和管理。
